For sale: One Swiss biotech with an antibiotic and a low tax rate

With the FDA insisting on more studies before it will consider approval of its new antibiotic and needing money to pay for them, Switzerland-based Basilea figures it might sell some assets to raise the money. And the assets it has are itself and its EU tax base, Bloomberg reported. And so the Basel-based biotech is offering itself up to any U.S.-based pharma that wants to make what might be called a tit for tax deal. Story

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.